Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 144 participants.

Also called NCT01974570

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 144 participants (enrolled count) (from the registry)
Sponsor
KGK Science Inc. (from the registry)
Registry
  • NCT NCT01974570
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada, Czechia, Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01974570. Randomized; triple masking; primary purpose prevention. Start 2013-11 (registry gives no type); primary completion 2015-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects
Condition
Prehypertension
Intervention (Dietary supplement)
Marealis refined peptide concentrate
Intervention (Dietary supplement)
Placebo
Lead sponsor
KGK Science Inc. (class: industry)
Collaborator
Marealis AS (class: industry)

Record details

Record id
cardio:ct-nct01974570
Content hash
9fe0c74286336c152230b7f41f32538e8b6cc8e91a3a8b7847f768184432db08